A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 28 Aug 2025
At a glance
- Drugs OD 07656 (Primary) ; Vedolizumab
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Odyssey Therapeutics
Most Recent Events
- 07 Jul 2025 This trial has been Withdrawn prior to enrolment in Hungary and not yet recruiting in Austria, Belgium, Croatia, Czechia, Lithuania, Poland countries, according to Clinical Trials Information System record.
- 04 Jul 2025 Status changed from not yet recruiting to recruiting.
- 05 Mar 2025 New trial record